| GSK-3αβ WT | GSK-3αβ KI | |||
|---|---|---|---|---|
| Control | Isoproterenol | Control | Isoproterenol | |
| LVMI (μl/g) | 2.9 ± 0.1 | 3.6 ± 0.2* | 2.9 ± 0.1 | 3.2 ± 0.1 |
| EDVI (μl/g) | 1.6 ± 0.1 | 1.6 ± 0.2 | 1.7 ± 0.1 | 3.1 ± 0.2*† |
| ESVI (μl/g) | 0.7 ± 0.1 | 1.3 ± 0.2* | 0.8 ± 0.1 | 1.7 ± 0.2* |
| SVI (μl/g) | 0.9 ± 0.04 | 0.3 ± 0.1* | 0.9 ± 0.1 | 1.4 ± 0.1*† |
| HR (min−1) | 511 ± 10 | 514 ± 8 | 517 ± 10 | 529 ± 7 |
| CI (μl/min.g) | 483 ± 21 | 164 ± 29* | 458 ± 38 | 713 ± 61*† |
| EF (%) | 57.5 ± 1.8 | 19.9 ± 3.6*† | 53.4 ± 1.9 | 44.3 ± 4.1 |
| LVd (mm) | 0.9 ± 0.04 | 1.2 ± 0.1*† | 0.9 ± 0.04 | 0.9 ± 0.03 |
| LVs (mm) | 1.4 ± 0.04 | 1.4 ± 0.1 | 1.4 ± 0.03 | 1.3 ± 0.1 |
| SWT (%) | 57.6 ± 5.4 | 16.3 ± 2.4* | 53.3 ± 7.5 | 44.1 ± 9.4 |
CI, cardiac index; EDVI, end-diastolic volume index; EF, ejection fraction; ESVI, end-systolic volume index; GSK-3, glycogen synthase kinase 3; GSK-3αβala21/ala9, KI; GSK-3αβser21/ser9, WT; HR, heart rate; LVd, left ventricle diastolic measurement; LVMI, left ventricular mass index; LVs, left ventricle systolic measurement; SVI, stroke volume index; SWT, systolic wall thickening. *p<0.05 versus control within genotype; †p<0.05 versus genotype.